Journal: Virology Journal
Article Title: Oncolytic activity of a coxsackievirus B3 strain in patient-derived cervical squamous cell carcinoma organoids and synergistic effect with paclitaxel
doi: 10.1186/s12985-024-02502-y
Figure Lengend Snippet: Oncolytic activity of CVB3/2035A in human CSCC cell lines and cell line-derived xenografts. (A) CSCC cell monolayers were either mock-infected or infected with CVB3/2035A at an MOI of 1. Photomicrographs were taken at 72 h post-infection. Scale bar, 100 μm. (B) CSCC cells were infected with CVB3/2035A at an MOI of 10, 1, 0.1, and 0.01 for 72 h. Cell viability was assessed using the CCK8 assay. (C) Nude mice bearing C33A, SiHa, and CaSki xenografts were treated i.t. or i.v. with five consecutive doses of CVB3/2035A (1 × 10 8 TCID 50 per dose). An equivalent volume of PBS was administered i.t. as a control (Mock). Tumor growth was monitored over a 20-day period. (D) The combination of CVB3/2035A and paclitaxel improved efficacy in CSCC CDX models. Nude mice with C33A, SiHa, and CaSki xenografts were either mock-treated (PBS i.t. + PTX diluting solution i.p.) or treated with CVB3/2035A (1 × 10 8 TCID 50 i.t. + PTX diluting solution i.p.), PTX (5 mg/kg i.p. + PBS i.t.), or a combination (1 × 10 8 TCID 50 CVB3/2035A i.t. + 5 mg/kg PTX i.p.). Data are presented as means ± SEM. Statistical analysis was performed using a two-way ANOVA ( n = 5). Black arrows indicate treatments; ns, not significant; * p < 0.05; **** p < 0.0001
Article Snippet: Three human CSCC cell lines (C33A, SiHa, and CaSki) were purchased from the American Type Culture Collection (ATCC).
Techniques: Activity Assay, Derivative Assay, Infection, CCK-8 Assay, Control